Organizational expansion sends Genmab costs soaring

The Danish biotech company has needed more hands on deck to help with something it has never done before: partnering up to commercialize of one of its own products.

Photo: Tuala Hjarnø / Genmab / PR

Genmab has been busy finding new staff after the successful launch of cervical cancer drug Tivdak (tisotumab vedotin) – the first product that the Danish biotech company is a part of commercializing itself.

Such efforts take their toll, which is evident in the company’s recently released second-quarter report from Wednesday, where Genmab revealed that general expenses relating to selling and administration have gone up 133% in the first half of 2022 compared to the same period in 2021, increasing costs by DKK 630m to DKK 1.1bn (USD 87.4m to USD 152.6m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs